Postpartum Period Linked to Higher Risk of Myasthenia Gravis Exacerbations

Myasthenia gravis (MG), a chronic autoimmune disorder causing fluctuating muscle weakness, frequently affects women during their reproductive years, creating significant clinical challenges during pregnancy [1, 2]. The disease course is often unpredictable, with historical data from small case series yielding inconsistent estimates of exacerbation risk [1, 2, 3]. Clinicians must balance maternal disease control against potential fetal risks, including the 10% to 20% chance of transient neonatal myasthenia gravis from transplacental autoantibody passage [4]. The specter of myasthenic crisis, a life-threatening respiratory complication, further complicates management [5, 2]. This uncertainty underscores the need for robust, population-level evidence to guide patient counseling and treatment. A recent nationwide cohort study from Sweden now provides a clearer, more reliable assessment of these risks.